MedTrace Logo

Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study

NCT05131646 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2024-03-04

Study results available
· View outcomes & findings →

Summary

This is an open-label, non-interventional extension study of up to 12 weeks in duration in subjects completing Cohorts 2, 3, and 4 of the Parent study, CLS1002-101.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

DRUG

CLS-AX

injectable suspension of small molecule tyrosine kinase inhibitor (TKI) administered in the Parent study CLS1002-101

Sponsors & Collaborators

  • Clearside Biomedical, Inc.

    lead INDUSTRY

Principal Investigators

  • Susan Coultas, PhD · Clearside Biomedical, Inc.

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-08
Primary Completion
2023-01-05
Completion
2023-01-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05131646 on ClinicalTrials.gov